BIIB240628C227500
- 2.67
- +0.67+33.50%
Biogen Newsroom
Rising Drug Costs Force a Third of Americans to Leave Prescriptions Unfilled: Report
Cassava Sciences Shares Plunge on Indictment Against Former Advisor -- Barrons.com
By Anita Hamilton A federal indictment of a lead scientist working as an advisor for Cassava Sciences, which has an Alzheimer's drug in late-stage clinical trials, sent shares sharply down Friday. T
Needham Maintains Biogen(BIIB.US) With Buy Rating, Maintains Target Price $294
Needham analyst Ami Fadia maintains $Biogen(BIIB.US)$ with a buy rating, and maintains the target price at $294.According to TipRanks data, the analyst has a success rate of 44.1% and a total average
Express News | Needham Reiterates Buy on Biogen, Maintains $294 Price Target
Biogen, Eisai Launch Leqembi in China to Treat Alzheimer's Disease
Biogen (BIIB) said Thursday it has launched the humanized anti-soluble aggregated amyloid-beta monoclonal antibody Leqembi in China with Eisai Co. Ltd. Leqembi received approval in January as a treatm
Eisai and Biogen Launch Alzheimer's Drug Leqembi in China
Express News | 'Biogen Is Pursuing More Dealmaking This Year, With Plans To Spend Up To $8B' - Endpoint News
FDA Accepts Ionis' (IONS) NDA for Rare Disease Drug Olezarsen
Forecasting The Future: 19 Analyst Projections For Biogen
Throughout the last three months, 19 analysts have evaluated Biogen (NASDAQ:BIIB), offering a diverse set of opinions from bullish to bearish.The following table summarizes their recent ratings, shedd
Is Biogen Stock Underperforming the Nasdaq?
Biogen Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/26/2024 41.44% RBC Capital $317 → $317 Reiterates Outperform → Outperform 06/05/2024 41.44% RBC Capital
RBC Capital Maintains Biogen(BIIB.US) With Buy Rating, Maintains Target Price $317
RBC Capital analyst Brian Abrahams maintains $Biogen(BIIB.US)$ with a buy rating, and maintains the target price at $317.According to TipRanks data, the analyst has a success rate of 49.2% and a total
Express News | 'Biogen Has Up To $10B For Its Next M&A Bets' - Bloomberg News
Biogen Inc. (BIIB) Is a Top-Ranked Momentum Stock: Should You Buy?
Express News | Tofidence™ (Tocilizumab), a Biosimilar Referencing Roactemra®, Approved in the European Union
Wells Fargo Maintains Biogen(BIIB.US) With Hold Rating, Maintains Target Price $240
Wells Fargo analyst Mohit Bansal maintains $Biogen(BIIB.US)$ with a hold rating, and maintains the target price at $240.According to TipRanks data, the analyst has a success rate of 59.3% and a total
Biogen to Report Second Quarter 2024 Financial Results August 1, 2024
Cambridge, Mass. - Biogen Inc. (Nasdaq:BIIB) today announced it will report second quarter 2024 financial results Thursday, August 1, 2024, before the financial markets open. Following the release of
Add Portfolio Diversity With These BMO Value Stock Picks
Investors Three-year Losses Continue as Biogen (NASDAQ:BIIB) Dips a Further 3.3% This Week, Earnings Continue to Decline
As an investor its worth striving to ensure your overall portfolio beats the market average. But its virtually certain that sometimes you will buy stocks that fall short of the market average returns
Ionis (IONS) Expands Licensing Deal With Otsuka for HAE Drug